U.S. Markets open in 6 hrs 43 mins
  • Crude Oil

    71.18
    +0.89 (+1.27%)
     
  • Gold

    1,762.20
    -1.60 (-0.09%)
     
  • Silver

    22.22
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1737
    +0.0010 (+0.0822%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3676
    +0.0017 (+0.1217%)
     
  • USD/JPY

    109.5570
    +0.1370 (+0.1252%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,074.60
    -59.79 (-5.27%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia.

  • The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.

  • The results were highlighted in a poster presentation at the International Association for the Study of Pain (IASP) World Congress.

  • IMC‑1 exhibited an encouraging safety profile, as adverse events occurred at a lower rate and were less severe in the IMC‑1 treatment group compared with placebo.

  • The discontinuation rate was nearly 3‑fold higher in patients receiving placebo than the IMC‑1 group, suggesting that treatment with IMC‑1 was unusually well‑tolerated.

  • Significant reductions in pain, fatigue, and other vital symptoms were observed.

  • Price Action: VIRI shares are up 12.1% at $6.30 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.